SCHEMBL3608858

SCHEMBL3608858

Cc1cnc(Nc2cccc(Cl)c2)nc1-c1cccnc1NCCCn1ccnc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.41
STK17A Q9UEE5 8/20 0.40
STK17B O94768 3/20 0.39
SYK P43405 1/20 0.38
SIRT5 Q9NXA8 1/20 0.38
KDR P35968 4/20 0.38
CDK1 P06493 4/20 0.38
CDK5 Q00535 3/20 0.37
CDK5R1 Q15078 3/20 0.37
MAPK1 P28482 2/20 0.37
CDK4 P11802 2/20 0.37
CCNB1 P14635 2/20 0.37
CCNA2 P20248 2/20 0.37
CCND1 P24385 2/20 0.37
CDK2 P24941 2/20 0.37
CDK7 P50613 2/20 0.37
CCNH P51946 2/20 0.37
NPC1 O15118 1/20 0.37
CCNT1 O60563 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607630 0.86 CDK2 (0.47) KDRCDK1CDK5CDK5R1MAPK1
SCHEMBL3608585 0.86 STK17A (0.45) AXLSTK17ASTK17BSYKSIRT5
SCHEMBL3608844 0.85 STK17A (0.56) STK17ASTK17B
SCHEMBL3609399 0.81 SIRT5 (0.49) STK17ASTK17BSYKSIRT5CDK1
SCHEMBL3616045 0.76 SYK (0.52) AXLSYKKDRCDK1CDK4
SCHEMBL3592504 0.71 SYK (0.50) AXLSYKKDRCDK4CDK2
SCHEMBL3603917 0.70 ABL1 (0.50) CDK1CDK5CDK5R1MAPK1CDK4
SCHEMBL3605884 0.69 CDK2 (0.53) CDK1CDK5CDK5R1MAPK1CDK4
SCHEMBL3603990 0.68 CAMK2D (0.60) STK17ASTK17BSYKCDK1CDK5
SCHEMBL3610465 0.68 CAMK2D (0.60) STK17ASTK17BSYKCDK1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048597-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 AXL 3611/4885STK17A 4710/4885STK17B 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.